Chemical resolution of (±)-calanolide A, (±)-cordatolide A and their 11-demethyl analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1079-1083

  Ma, Tao ^a   Gao, Qi ^a   Chen, Zhiwei ^b   Wang, Lin ^a   Liu, Gang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Calanolide A; Chemical resolution; Cordatolide A; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; CALANOLIDE A; CORDATOLIDE A; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRANOCOUMARIN DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; DIASTEREOISOMER; DRUG CYTOTOXICITY; DRUG INHIBITION; ENANTIOMER; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; OPTICAL ROTATION; STRUCTURE ACTIVITY RELATION; VIRUS CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG EFFECT; STEREOISOMERISM; SYNTHESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; HIV-1; MOLECULAR STRUCTURE; PYRANOCOUMARINS; STEREOISOMERISM;

EID: 38749120598     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.008     Document Type: Article

References (22)

1. Wang L., Ma T., and Liu G. Medicinal Chemistry of Bioactive Natural Products (Chapter 8) (2006) 325 and references therein
2. Kashman Y., Gustafson K.R., Fuller R.W., Cardellina J.H., McMahon J.B., Currens M.J., Buckheit R.W., Hughes S.H., Cragg G.M., and Boyd M.R. J. Med. Chem. 35 (1992) 2735
3. Ma T.; Wang L.; Liu G. Oral presentation at the 40th IUPAC Congress, Beijing, August 15-19, 2005, p 207.
4. Xu Z.Q., Barrow W.W., Suling W.J., Westbrook L., Barrow E., Lin Y.M., and Flavin M.T. Bioorg. Med. Chem. 12 (2004) 1199
5. Chenera B., West M.L., Finkelstein J.A., and Dreyer G.B. J. Org. Chem. 58 (1993) 5605
6. Kucherenko A., Flavin M.T., Boulanger W.A., Khilevich A., Shone R.L., Rizzo J.D., Sheikman A.K., and Xu Z.Q. Tetrahedron Lett. 36 (1995) 5475
7. Zhou C.M., Wang L., Zhang M.L., Zhao Z.Z., Zhang X.Q., Chen X.H., and Chen H.S. Chin. Chem. Lett. 9 (1998) 433
8. Zhou C.M., Wang L., Zhang M.L., Zhao Z.Z., Zhang X.Q., Chen X.H., and Chen H.S. Acta Pharm. Sin. 34 (1999) 673
9. Palmer C.J., and Josephs J.L. Tetrahedron Lett. 35 (1994) 5363
10. Deshpande P.P., Tagliaferri F., Victory S.F., Yan S.J., and Baker D.C. J. Org. Chem. 60 (1995) 2964
11. Trost B.M., and Toste F.D. J. Am. Chem. Soc. 120 (1998) 9074
12. Tanaka T., Kumamoto T., and Ishikawa T. Tetrahedron Lett. 41 (2000) 10229
13. Sekino E., Kumamoto T., Tanaka T., Ikeda T., and Ishikawa T. J. Org. Chem. 69 (2004) 2760
14. Khilevich A., Mar A., Flavin M.T., Rizzo J.D., Lin L., Dzekhtser S., Brankovic D., Zhang H.P., Chen W., Liao S.Y., Zembower D.E., and Xu Z.Q. Tetrahedron: Asymmetry 7 (1996) 3315
15. Cardellina J.H., Bokesch H.R., McKee T.C., and Boyd M.R. Bioorg. Med. Chem. Lett. 5 (1995) 1011
16. Flavin M.T., Rizzo J.D., Khilevich A., Kucherenko A., Sheinkman A.K., Vilaychack V., Lin L., Chen W., Greenwood E.M., Pengsuparp T., Pezzuto J.M., Hughes S.H., Flavin T.M., Cibulski M., Boulanger W.A., Shone R.L., and Xu Z.Q. J. Med. Chem. 39 (1996) 1303
17. Wang L.; Liu G.; Gao Q.; Ma T.; Zhao Z. Z. Chinese patent application for invention No. 03123628.6.
18. Liu G.; Ma T.; Chen Z. W.; Wang L. Chinese patent application for invention No. 200610098615.8.
19. 5: C, 70.77; H, 6.79. Found: C, 70.71; H, 6.75.
20. Chen Z.W., Zhou P., Ho D.D., Landau N.R., and Marx P.A. J. Virol. 71 (1997) 2705
21. HIV inhibition assay. A serial diluted drug (10 μM, 1 μM, 100 nM, 10 nM, 1 nM, and 0.1 nM), was tested against 100 TCID50 HIVADA infection in a pseudovirus-based assay. The assay quantifies the activity of a drug to inhibit HIV-induced reporter luciferase activity. The viral infection was determined on day 3 by measuring the reporter luciferase activity in TZM. CD4+. CCR5+ cells post-infection using commercially available kits. Antiviral data were reported as the quantity of drug required to inhibit production by percentage. Controls include (1) infected cells without adding any drugs as a baseline, (2) pseudovirus with non-specific envelope (e.g., HCV) which cannot infect TZM. CD4+. CCR5+ cells, and (3) an HIV-specific RT inhibitor as a positive control (e.g. AZT). The cell toxicity of the compounds against HIV was evaluated by similar microtiter assays with TZM. CD4+. CCR5+ and Vero cells. Serial diluted drugs (10 mM, 1 mM, 100 μM, 10 μM, 1 μM and 0.1 μM) were tested in cells using the cell viability assay which is commercially available (Promega). The toxicity data are reported as the quantity of a drug required to reduce cell viability by percentage.
22. Galinis D.L., Fuller R.W., Mckee T.C., Cardellina J.H., Gulakowski R.J., Mcmahon J.B., and Boyd M.R. J. Med. Chem. 39 (1996) 4507